Matasar Discusses Odronextamab and the ELM-1 Trial
Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.
Matthew Matasar, MD, chief of the division of blood disorders at the Rutgers Cancer Institute and professor at the Rutgers Robert Wood Johnson Medical School, discusses the mechanism of action of odronextamab (Ordspono) and the ongoing phase 1 ELM-1 (NCT02290951) trial evaluating the safety and tolerability of odronextamab in patients with CD20-positive B-cell malignancies who have previously received CD20-directed antibody therapy (NCT02290951).
Transcription:
0:10 | We have long understood that while CAR T cell therapy has changed the landscape of relapse and refractory large cell lymphoma, there definitely remains unmet need. Certainly, loss of CD19 can limit our ability to administer subsequent CD19-directed treatments, and we know in general that bispecific antibodies are active in the management of aggressive B-cell lymphomas. So the question being posed here in this sub-analysis from ELM-1 is the activity of odronextamab as monotherapy in the treatment of diffuse large B-cell lymphoma relapsing after CAR T-cell therapy.
0:47 | Odronextamab is a bispecific antibody targeting both CD20 on the surface of malignant B-cells and CD3 on healthy native T-cells. These bispecific antibodies, such as odronextamab, create an immune synapse, allowing for T-cell activation, proliferation, and T-cell-mediated B-cell killing. We have extensive data from odronextamab and other similar molecules that these bispecific antibodies can be effective in treating aggressive B-cell lymphoma, even after the failure of prior lines of therapy. So here, we pose the question of whether odronextamab could be an appropriate treatment for patients that have been failed by CD19-targeting CAR T-cell therapy, understanding that patients who have been failed by CD19 CAR represent an area of tremendous unmet need, and these are patients with, unfortunately, very poor prognosis in the absence of standard treatments.
REFERENCE:
- Matasar M, Topp MS, Allan JN, et al. Efficacy and safety of odronextamab monotherapy in patients (Pts) with diffuse large B-cell lymphoma (DLBCL) progressing after CAR T-cell therapy: Primary analysis from the ELM-1 study. Blood. 2024;144(supplement 1):866. doi:10.1182/blood-2024-199155
